Source - RNS
RNS Number : 6371K
Circassia Pharmaceuticals Plc
12 April 2018

Circassia Pharmaceuticals PLC

Notice of Preliminary Results


Oxford, UK - 12 April 2018: Circassia Pharmaceuticals plc (LSE: CIR) will announce its preliminary results for the year ended 31 December 2017 on Tuesday 24 April 2018.


A presentation for analysts will take place at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD at 9.30am.  A webcast of the presentation will be available on the Company's website.


For further information please contact:


FTI Consulting

Mo Noonan

+44 (0) 20 3727 1000


About Circassia


Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. The Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the US commercial rights to COPD product Duaklir®.


Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide® pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide® pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products. For more information on Circassia please visit


This information is provided by RNS
The company news service from the London Stock Exchange